Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENB003 + Pembrolizumab in Advanced Solid Tumors
NCT04205227Phase 2Active, not recruiting
- Sponsor
- ENB Therapeutics
- Start
- Feb 2020
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ENB-003 in solid tumor (advanced stage), Malignant Melanoma (MM), ovarian cancer, pancreatic cancer (PC), squamous cell carcinoma of the head and neck (HNSCC), sponsored by ENB Therapeutics. Started Feb 2020; status: active, not recruiting.
02
Drugs
ENB-003
03
Conditions
solid tumor (advanced stage)Malignant Melanoma (MM)ovarian cancerpancreatic cancer (PC)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT04205227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04205227.